Lisata Therapeutics wins US method-of-use patent for certepetide in pancreatic cancer, solid tumors
Bitget2026/10/08 12:04Lisata Therapeutics won a new US method-of-use patent for certepetide covering combination treatment of pancreatic cancer and other solid tumors. The patent expires in May 2041. Management said the grant supports market exclusivity into November 2043. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841700) on October 08, 2026, and is solely responsible for the information contained therein.
- Lisata Therapeutics won a new US method-of-use patent for certepetide covering combination treatment of pancreatic cancer and other solid tumors.
- The patent expires in May 2041.
- Management said the grant supports market exclusivity into November 2043.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
